期刊文献+

马来酸依那普利片的药动学及相对生物利用度 被引量:5

Pharmacokinetics and relative bioavailability of the enalapril maleate tablets
下载PDF
导出
摘要 目的研究马来酸依那普利片在健康人体内的药动学及相对生物利用度。方法用双周期交叉实验设计,采用液相色谱-质谱-质谱联用法测定18名健康男性受试者口服马来酸依那普利片(受试制剂)和悦宁定(参比制剂)后不同时刻血浆中依那普利和其活性代谢物依那普利拉的浓度,绘制血药浓度-时间曲线并计算主要药动学参数。结果18名受试者口服含马来酸依那普利20 mg的受试制剂和参比制剂后血浆中依那普利的tm ax分别为(0.83±0.44)和(0.93±0.37)h,ρm ax分别为(70.54±26.84)和(67.01±23.75)μg.L-1,t1/2分别为(2.13±0.52)和(2.14±0.42)h,AUC0t-分别为(122.82±45.31)和(121.45±43.06)μg.h.L-1,AUC0-∞分别为(123.77±45.36)和(122.55±43.32)μg.h.L-1;依那普利拉的tm ax分别为(3.72±1.18)和(3.61±0.92)h,ρm ax分别为(33.14±9.72)和(34.15±10.98)μg.L-1,t1/2分别为(8.88±1.35)和(8.99±1.09)h,AUC0-t分别为(301.64±82.71)和(316.47±99.09)μg.h.L-1,AUC0-∞分别为(307.32±83.54)和(322.70±100.67)μg.h.L-1,以AUC0-t计算,马来酸依那普利的平均相对生物利用度为(103.0±20.1)%,依那普利拉的平均相对生物利用度为(98.4±22.4)%。结论根据双单侧检验表明2种制剂具有生物等效性。 Objective To study pharmacokinetics and relative bioavailability of enalapril maleate tablets in healthy volunteers. Methods A LC/MS/MS method was developed to determine the plasma concentrations of enalapril and its major active metabolite enalaprilat in 18 healthy Chinese male volunteers following a 20 mg dose of enalapril tablets( test formulation)and renitec(reference formulation)with two cross-over design, the blood concentration-time curves were plotted and the main pharmacokinetic parameters were calcu-lated. Results The main pharmacokinetic parameters of enalapril were: tmax(0.83±0.44) and(0.93±0.37)h,pmx(70.54±26. 84)and(67.01±23.75)μg·L^-1,t1/2 (2.13±0.52)and(2.14±0.42) h, AUC0-t(122.82±45.31) and(121.45±43.06)μg·L^-1,AUC0-∞(123.77±45.36) and(122.55±43.32)μg·L^-1, respectively. The main pharmacokinetic parameters of enalaprilat were: tmax(3.72±1.18) and(3.61±0.92)h,pmax(33.14±9.72) and(34.15±10.98)μg·L^-1,t1/2(8.88±1.35)and(8.99±1.09)h,AUC0-t(301.64±82.71) and (316.47±99.09)μg·L^-1, AUC0-∞(307.32±83.54) and (322.70±100.67)μg·L^-1, respectively. According to AUC0-t, the relative bioavailability of enalapril maleate and enalaprilat were(103.0±20.1)% and (98.4±22.4)%, respectively. Conclusions According to the two one-sided t-test, the two formulations are bioequivalent.
出处 《沈阳药科大学学报》 CAS CSCD 北大核心 2009年第12期991-996,共6页 Journal of Shenyang Pharmaceutical University
关键词 马来酸依那普利 依那普利拉 药动学 相对生物利用度 生物等效性 液相色谱-质谱-质谱联用法 enalapril maleate enalaprilat pharmacoldnetics relative bioavailability bioequivalence LC/ MS/MS
  • 相关文献

参考文献20

  • 1刘芸.依那普利[J].中国药学杂志,1994,29:507-509. 被引量:3
  • 2SMITH D H. Treamaent of hypertension with an an giotensin II -receptor antagonist compared with an angiotensin-converting enzyme inhibitor: a review of clinical studies of telmisartan and enalapril [ J ]. Clin Ther,2002,24(10) : 1484 - 1501. 被引量:1
  • 3许国,倪艳红.依那普利的临床药理及应用[J].云南民族学院学报(自然科学版),2000,9(3):184-186. 被引量:2
  • 4MATALKA K,ARAFAT T,HAMAD M,et al. Determination of enalapril and enalaprilat by enzyme linked immunosorbent assays: application to pharmacokinetie and pharmacodynarnic analysis [ J ]. Fundam Clin Pharmacol,2002,16 ( 3 ) : 237 - 244. 被引量:1
  • 5RAYMOND P, DRAPEAU G, RAUT R, et al. Quantification of des-arg9-bradykinin using a chemilumines- cence enzyme immunoassay:application to its kinetic profile during plasma activation[ J]. J Immunol Methods,1995,180(2) :247 -257. 被引量:1
  • 6WORLAND P J, JARROTT B. Radioimmunoassay for the quantitation of lisinopril and enalaprilat [ J ]. J Pharm Sci, 1986,75(5) :512 -516. 被引量:1
  • 7YUAN A S, GILBERT J D. Time-resolved fluoroimmunoassay for the determination of lisnopril and enalaprilat in human serum [ J ]. J Pharm Biomed Anal, 1996,14:773 -781. 被引量:1
  • 8SHIOYA H, SHIMOJO M, KAWAHARA Y. Dtemination of enalapril and its active metabolite enalaprilat in plasma and urine by gas chromatography/mass spectrometry[ J ]. Biomed Chromatogr, 1992,6: 59 - 62. 被引量:1
  • 9谭力,张昕,袁倚盛.马来酸依那普利片的药物动力学及相对生物利用度[J].中国药科大学学报,1999,30(5):350-352. 被引量:8
  • 10王淑君,姜晓薇,孙进,刘霄,陈济民.HPLC法测定依那普利的血药浓度[J].沈阳药科大学学报,2003,20(5):349-351. 被引量:12

二级参考文献31

共引文献606

同被引文献26

引证文献5

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部